UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) Commission file number 001-41952 Telomir Pharmaceuticals, Inc. ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________to _______________ (Exact name of registrant as specified in its charter) Regis ...

Core Insights - New findings indicate that Telomir-1 significantly impacts CASP8 and GSTP1, which are essential genes involved in regulating cell death and detoxification pathways often altered in cancer [1] Company Summary - Telomir Pharmaceuticals, Inc. is a pre-clinical biotechnology company focused on developing therapies that address the epigenetic causes of cancer, aging, and age-related diseases [1] - The company reported new preclinical data from an in vivo study involving mice with human aggressive prostate cancer tumors [1] Research Findings - The study evaluated DNA-methylation changes in the defense genes CASP8 and GSTP1 after treatment with oral Telomir-1, Rapamycin, chemotherapy, and combination regimens [1]

Core Insights - Telomir Pharmaceuticals, Inc. has executed a binding Letter of Intent to acquire TELI Pharmaceuticals, Inc., which will secure worldwide rights to its lead investigational therapy, Telomir-1 [1] - The agreement aims to unify global IP rights and enable up to $5 million in potential shareholder contributions, strengthening Telomir's foundation for partnerships, licensing, and long-term value creation [1] Company Overview - Telomir Pharmaceuticals is a preclinical-stage biotechnology company focused on developing therapies targeting epigenetic drivers of cancer, aging, and age-related diseases [1]

Core Insights - Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) has seen a significant increase in stock price, rising 20.30% to $1.98, with a trading volume of 21.60 million shares compared to the average of 4.9 million shares [1][5]. Group 1: Drug Candidate Performance - The lead drug candidate, Telomir-1, has demonstrated a significant reduction in the viability of aggressive triple-negative breast cancer (TNBC) cells in laboratory studies, showing a clear, dose-dependent effect [2]. - Telomir-1's efficacy is linked to its ability to regulate cellular iron and energy balance, as evidenced by the recovery of cancer cells when iron was reintroduced [2]. Group 2: Mechanism of Action - Telomir-1 has been shown to reset abnormal DNA methylation patterns and restore balanced gene expression in cancer models, particularly in TNBC where iron-dependent enzymes contribute to aggressive cancer behavior [3]. Group 3: Future Plans - The company plans to expand its research to include additional cancer types, such as pancreatic cancer and leukemia, and will conduct further animal studies in preparation for an Investigational New Drug (IND) submission [4].

Core Findings - Telomir Pharmaceuticals, Inc. announced new preclinical results indicating that its investigational therapy Telomir-1 can restore the body's natural tumor suppressor defenses by reversing abnormal DNA methylation of key genes MASPIN and RASSF1A in aggressive prostate cancer models [1] Group 1: Company Overview - Telomir Pharmaceuticals is a preclinical-stage biotechnology company focused on developing therapies that target epigenetic drivers of cancer, aging, and age-related diseases [1] Group 2: Research Findings - Telomir-1 reactivates two critical tumor suppressor genes, MASPIN and RASSF1A, which are essential for blocking invasion, limiting metastasis, and improving chemotherapy responsiveness in prostate cancer [1]

Market Overview - U.S. stock futures declined on Tuesday following mixed movements on Monday, with major benchmark indices showing lower futures [1] - The Advanced Micro Devices Inc. (NASDAQ:AMD) deal with OpenAI contributed to a rally in AI-linked stocks, which has been a driving force behind Wall Street's bull run this year [1] Economic Indicators - The U.S. government shutdown, now in its seventh day, has delayed the release of the U.S. trade deficit data [2] - The 10-year Treasury bond yield is at 4.17%, while the two-year bond yield stands at 3.59% [2] - Market expectations indicate a 92.5% likelihood of the Federal Reserve cutting interest rates in its upcoming October meeting [2] Futures Performance - Dow Jones futures decreased by 0.18%, S&P 500 by 0.08%, Nasdaq 100 by 0.04%, and Russell 2000 by 0.13% [3] - The SPDR S&P 500 ETF Trust (NYSE:SPY) fell by 0.037% to $671.36, while Invesco QQQ Trust ETF (NASDAQ:QQQ) rose by 0.0099% to $607.77 in premarket trading [3] Stocks in Focus - Trilogy Metals Inc. (NYSE:TMQ) surged by 180.38% in premarket trading after the White House announced a $35.6 million investment for a 10% stake to support mining exploration in Alaska's Ambler Mining District [8] - Advanced Micro Devices Inc. (NASDAQ:AMD) increased by 2.57% following a deal with OpenAI to supply Instinct GPU accelerators for AI infrastructure [9] - Applovin Corp. (NASDAQ:APP) fell by 2.56% amid an SEC investigation into its data-collection practices [10] - Telomir Pharmaceuticals Inc. (NASDAQ:TELO) jumped by 30.99% after releasing promising preclinical study results for its lead compound [11] Analyst Insights - Corporate America is expected to deliver a strong earnings season for Q3 2025, with a forecasted low-teens earnings growth rate for the S&P 500 [16] - Factors contributing to this outlook include a resilient economy, strong AI investment, and a weaker U.S. dollar [17] - Analysts predict a 5% earnings beat above current consensus estimates for the third quarter, despite potential tariff pressures [18]

Earnings Expectations - Wall Street anticipates McCormick & Company Inc. to report quarterly earnings of 81 cents per share with revenue projected at $1.71 billion [2] - Analysts expect Penguin Solutions Inc. to post quarterly earnings of 38 cents per share on revenue of $342.11 million [2] - Saratoga Investment Corp. is expected to report quarterly earnings of 68 cents per share with revenue of $31.98 million [2] Stock Performance - McCormick shares increased by 1.3% to $69.19 in after-hours trading [2] - SANUWAVE Health Inc. shares fell by 19.2% to $33.00 after issuing preliminary third-quarter revenue results below estimates and cutting FY25 revenue guidance from $48 million-$50 million to $44 million-$46 million [2] - Penguin Solutions shares rose by 1.7% to $29.80 in after-hours trading [2] - Telomir Pharmaceuticals Inc. shares surged by 38.7% to $1.97 following promising preclinical study results for its lead compound, Telomir-1 [2]

Group 1: Telomir Pharmaceuticals Inc. (TELO) - Shares surged 43% in after-hours trading, climbing from $1.42 to $2.03 on light volume of 213,569 shares, below the average daily volume of 4.67 million [2] - The spike reflects renewed interest in recent in vitro data showing Telomir-1's ability to target additional histone demethylase families, indicating a unique epigenetic profile [3] Group 2: Processa Pharmaceuticals Inc. (PCSA) - Shares rose 32.6% in after-hours trading to $0.37, following a 30.9% gain during the regular session, with a closing price of $0.2790 on volume exceeding 31.9 million shares [4] - The price movement occurred without any official news or updates from the company, suggesting speculative momentum or technical positioning [5] Group 3: Reviva Pharmaceuticals Holdings Inc. (RVPH) - Shares increased 33.7% in after-hours trading to $0.8950 after a regular session gain of 22.8%, closing at $0.6693 with significant trading volume of 34.2 million shares [6] - The rally happened despite no recent official news, with the last update being four days prior regarding a healthcare conference [7] Group 4: NeuroOne Medical Technologies Corp. (NMTC) - Shares rose 9.5% in after-hours trading to $1.09, extending a 7.1% gain during the regular session, with a closing price of $0.9956 and trading volume of 1.21 million shares [8] - The increase followed the announcement of preliminary unaudited product revenue of $9.1 million for fiscal year 2025, up 163% from the prior year, and an upcoming virtual webinar [9] Group 5: BioRestorative Therapies Inc. (BRTX) - Shares edged 4.6% higher in after-hours trading to $1.60, following a modest 2% gain during the regular session, with a closing price of $1.53 and trading volume of 415,798 shares [10] - The increase followed the announcement of a $1.085 million registered direct offering priced at $1.60 per share, with proceeds aimed at advancing clinical trials and other corporate purposes [11]

Core Viewpoint - Telomir Pharmaceuticals Inc. experienced a significant stock price increase of 38.71% in after-hours trading following the announcement of promising preclinical study results for its lead compound, Telomir-1, which is aimed at reversing DNA methylation in aggressive prostate cancer models [1][2]. Group 1: Study Results - Telomir-1 was reported to reverse abnormal DNA methylation, restoring the function of key tumor suppressor genes MASPIN and RASSF1A, which are often silenced in cancer due to hypermethylation [2][3]. - MASPIN is critical for blocking tumor invasion, regulating cell migration, promoting apoptosis, and enhancing treatment sensitivity. Telomir-1 effectively restored MASPIN activity in vivo by reversing chemotherapy-induced DNA methylation [4]. - RASSF1A is involved in cell cycle control, promoting apoptosis, and suppressing metastasis. Telomir-1 reduced RASSF1A methylation in a dose-dependent manner, with enhanced effects when combined with chemotherapy [5]. Group 2: Development Status - The company is continuing preclinical development with IND-enabling studies for Telomir-1 [6]. Group 3: Stock Performance - Year-to-date, TELO stock is down 65.53%, but has gained 15.45% over the past month. The stock has traded between $1.12 and $7.08 over the past year, with a market capitalization of $45.84 million and an average daily trading volume of 3.33 million shares [7].

Core Insights - Telomir Pharmaceuticals, Inc. has announced new in vitro results indicating that Telomir-1 adds KDM5 family inhibition to its previously reported KDM2/KDM6 and DNA methylation activity, suggesting a potential advancement in epigenetic therapy [1] Company Summary - Telomir Pharmaceuticals, Inc. is a preclinical-stage biotechnology company focused on developing therapies that target the root causes of cancer, aging, and age-related diseases [1] - The company is listed on NASDAQ under the ticker TELO [1] Industry Summary - The results from Telomir-1 may represent a novel frontier in epigenetic therapy, an area where no existing candidates have demonstrated comparable breadth [1] - The inhibition of three members of the KDM5 histone demethylase family by Telomir-1 highlights the potential for innovative therapeutic approaches in the field of epigenetics [1]